While prostate cancer is generally regarded as a low–mutation-burden tumor [11] and immune-checkpoint blockade has resulted in only modest benefits as a monotherapy [12, 13], recent data have suggested that AR-V7-expressing prostate cancers may be associated with a greater number of DNA-repair gene mutations and a higher mutation load [14]. The gene discussed is AR; the disease is Familial prostate cancer.